Paper4856629
Structure-antitumor activity relationships among quinone derivatives.
Driscoll JS and 3 others. Cancer Chemother Rep 2, 1974. Cited by 71 papers, by iCite.
Cite this record
ConductScience Library. Structure-antitumor activity relationships among quinone derivatives. Papers, record 4856629. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4856629
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Quinones | Major topic |
| Animals | |
| Anthraquinones | |
| Azirines | |
| Bridged-Ring Compounds | |
| Carcinoma 256, Walker | |
| Daunorubicin | |
| Drug Evaluation, Preclinical | |
| Heterocyclic Compounds | |
| L-Lactate Dehydrogenase | |
| Leukemia L1210 | |
| Mice | |
| Mitomycins | |
| Naphthoquinones | |
| Neoplasms, Experimental | |
| Sarcoma 180 | |
| Streptonigrin | |
| Structure-Activity Relationship |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 71 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36570217 | Nanotherapeutic Intervention in Photodynamic Therapy for Cancer. | ACS Omega | 2022 | https://conductscience.org/library/papers/36570217 | PubMed |
| 33519476 | Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33519476 | PubMed |
| 32318101 | Antioxidant Properties of Lapachol and Its Derivatives and Their Ability to Chelate Iron (II) Cation: DFT and QTAIM Studies. | Bioinorg Chem Appl | 2020 | https://conductscience.org/library/papers/32318101 | PubMed |
| 30959841 | Juglone in Oxidative Stress and Cell Signaling. | Antioxidants (Basel) | 2019 | https://conductscience.org/library/papers/30959841 | PubMed |
| 30689661 | Lapachol and synthetic derivatives: in vitro and in vivo activities against Bothrops snake venoms. | PLoS One | 2019 | https://conductscience.org/library/papers/30689661 | PubMed |
| 29651389 | The Healing Effect of N-Hexan- Dichloromethane Extract Root Onosma Bulbotrichum in Second Degree Burns. | World J Plast Surg | 2018 | https://conductscience.org/library/papers/29651389 | PubMed |
| 21201931 | 2,3-Bis(2-chloro-benz-yl)naphthalene-1,4-dione. | Acta Crystallogr Sect E Struct Rep Online | 2008 | https://conductscience.org/library/papers/21201931 | PubMed |
| 9559016 | Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. | CMAJ | 1998 | https://conductscience.org/library/papers/9559016 | PubMed |
| 7196864 | The immunoinhibitory and immunostimulatory effects of hydroxyanthra- and hydroxynaphthoquinone derivatives. | Folia Microbiol (Praha) | 1981 | https://conductscience.org/library/papers/7196864 | PubMed |
| 6819097 | Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6819097 | PubMed |
| 6584903 | Mutagenicity of quinones: pathways of metabolic activation and detoxification. | Proc Natl Acad Sci U S A | 1984 | https://conductscience.org/library/papers/6584903 | PubMed |
| 6381377 | Diaziquone (AZQ). | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6381377 | PubMed |
| 4056853 | Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma. | J Neurooncol | 1985 | https://conductscience.org/library/papers/4056853 | PubMed |
| 4005142 | Selective toxicity of 1-naphthol to human colorectal tumour tissue. | Br J Cancer | 1985 | https://conductscience.org/library/papers/4005142 | PubMed |
| 3965159 | Human pharmacokinetics of marcellomycin. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3965159 | PubMed |
| 3838738 | Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3838738 | PubMed |
| 3746385 | Response variability of human brain tumors to AZQ in tissue culture. | J Neurooncol | 1986 | https://conductscience.org/library/papers/3746385 | PubMed |
| 3700042 | High dose AZQ in renal cancer. A Southwest Oncology Group phase II study. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3700042 | PubMed |
| 3307874 | Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? | Br J Cancer Suppl | 1987 | https://conductscience.org/library/papers/3307874 | PubMed |
| 2993536 | Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study. | J Neurooncol | 1985 | https://conductscience.org/library/papers/2993536 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4856629
GET https://conductscience.org/api/papers/v1/4856629/cited_by?page=2